Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.

About this update from Gentherm Inc

[{"type":"text","content":"Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025","length":76,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on Investee company, InStatin.","length":331,"tagName":"p"},{"type":"text","content":"InStatin, a biotechnology company developing inhaled statin therapies for respiratory diseases, today reported significant progress from June 2024 through December 2025, despite a challenging investment climate. The company has refined its clinical strategy, advanced its lead molecule, and expanded its leadership and advisory teams.","length":334,"tagName":"p"},{"type":"text","content":""Despite capital headwinds, we have made disciplined and meaningful progress across our pipeline, team, and strategy," said InStatin's CEO, Andy Clark. "Our decision to expand our focus to include COPD as a lead indication and continue to include asthma in our development plans, reflects a clear path to addressing 2 major unmet needs with the same dosing and product, and the promising preclinical data for INS-102 gives us strong momentum heading into 2026."","length":485,"tagName":"p"},{"type":"text","content":"Key Developments:Focus on COPD: Following input from its expanded Clinical Advisory Board, InStatin has designated Chronic Obstructive Pulmonary Disease (COPD) as its lead clinical indication for inhaled statin therapy, based on clear unmet medical and commercial need.","length":270,"tagName":"p"},{"type":"text","content":"New Lead Molecule: Preclinical studies identified INS-102 as the company's new lead statin candidate, demonstrating improved pharmacokinetics (PK) and longer lung residence time compared to earlier candidates. A proprietary dry powder formulation has undergone PK testing successfully in animals.","length":300,"tagName":"p"},{"type":"text","content":"Dr. Amir Zeki, Chief Scientific and Medical Officer, commented: "Transitioning to INS-102 was a data-driven decision. It enhances lung retention profile in preclinical models and positi...

More updates from Gentherm Inc